A direct effect of Dasatinib on metabolic pathways is suggested by the previous finding that the TKI protected against glucose intolerance through the upregulation of Peroxisome proliferator-activated receptor gamma coactivator (PGC)-1a expression in white adipose tissue [49]. Here, PPARGC1A is linked to Glucose intolerance.